Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Post by Chainsawwon Jan 31, 2017 10:23am
236 Views
Post# 25777156

Promis needs to arrange purchase of Goldman stock position

Promis needs to arrange purchase of Goldman stock positionFor over 6 months Goldman has been selling in the face of any stock price advance.  
This morning they sold already 250,000 shares.  

Most companies think it is better to just let the market just work it out and eventually it will land in better hands.   This is dumb thinking.  The stock price needs to be protected and that is why Mackie was brought in to make a semblance of a market.

Anybody know who is this huge stockholder from Goldman and how much they have left??

The company needs to arrange a cross trade to relieve Goldman from their position so the market does not get beat back every day for months and months.  Surely someone like M. Bigger may be interested and then the stock will continue to move up and not get hammered all the time.
Bullboard Posts